Oral nifedipine may be a preferential option for treating acute severe hypertension during pregnancy: a meta-analysis

References

• Luger RK, Kight BP. Hypertension in Pregnancy. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022, StatPearls Publishing LLC; 2022.
   Google Scholar
• Hutcheon JA, Lisonkova S, Joseph KS. Epidemiology of pre-eclampsia and the other hypertensive disorders of pregnancy. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):391–10.
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–2128. DOI:10.1016/S0140-6736(12)61728-0
   PubMed Web of Science ®Google Scholar
• Khan KS, Wojdyla D, Say L, et al. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367(9516):1066–1074.
   PubMed Web of Science ®Google Scholar
• Duro-Gomez J, Rodriguez-Marin AB, Gimenez de Azcarete M, et al. A trial of oral nifedipine and oral labetalol in preeclampsia hypertensive emergency treatment. J Obstet Gynaecol. 2017;37(7):864–866. DOI:10.1080/01443615.2017.1308321
   PubMedGoogle Scholar
• Shekhar S, Gupta N, Kirubakaran R, et al. Oral nifedipine versus intravenous labetalol for severe hypertension during pregnancy: a systematic review and meta-analysis. BJOG: An Int J Obstetrics & Gynaecol. 2016;123(1):40–47.
   PubMed Web of Science ®Google Scholar
• Nelson-Piercy C LWM. Nelsonpiercy C ea. 9 pregnancy and chronic hypertension: nifedipine vs labetalol as antihypertensive treatment (the panda study): anti-hypertensive medications. Pregnancy Hypertens Int J Womens Cardiovasc Health. 2016;6(3):141–.
   Google Scholar
• Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: iSSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018;13:291–310.
   PubMed Web of Science ®Google Scholar
• Committee A. Gestational hypertension and preeclampsia. Obstet Gynecol. 2019;133:e1–25.
   Web of Science ®Google Scholar
• Lowe SA, Brown MA, Dekker GA, et al. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust NZ J Obstetrics Gynaecol. 2009;49(3):242–246. DOI:10.1111/j.1479-828X.2009.01003.x
   PubMed Web of Science ®Google Scholar
• Bertani H, Gelmini R, Del Buono MG, et al. Literature overview on artificial liver support in fulminant hepatic failure: a methodological approach. Int J Artif Organs. 2002;25(10):903–910. DOI:10.1177/039139880202501002
   PubMed Web of Science ®Google Scholar
• Magee LA, Pels A, Helewa M, et al. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens. 2014;4(2):105–145.
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Ws. Children’s H. National Institute for Health and Clinical Excellence: guidance. Hypertension in Pregnancy: the Management of Hypertensive Disorders During Pregnancy. London: RCOG Press Copyright © 2022, StatPearls Publishing LLC; 2022.
   Google Scholar
• Duley L, Meher S, Jones L. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev. 2013;2013(7). DOI:10.1002/14651858.CD001449.pub3
   PubMedGoogle Scholar
• Firoz T, Magee LA, MacDonell K, et al. Oral antihypertensive therapy for severe hypertension in pregnancy and postpartum: a systematic review. BJOG. 2014;121(10):1210–1218. doi: 10.1111/1471-0528.12737. discussion 20.
   PubMed Web of Science ®Google Scholar
• Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ. 2003;327(7421):955–960.
   PubMed Web of Science ®Google Scholar
• Magee LA, Ornstein MP, von Dadelszen P. Fortnightly review: management of hypertension in pregnancy. BMJ. 1999;318(7194):1332–1336.
   PubMed Web of Science ®Google Scholar
• Shi Q, Leng W, Yao Q, et al. Oral nifedipine versus intravenous labetalol for the treatment of severe hypertension in pregnancy. Int J Cardiol. 2015;178:162–164.
   PubMed Web of Science ®Google Scholar
• Zulfeen M, Tatapudi R, Sowjanya R. IV labetalol and oral nifedipine in acute control of severe hypertension in pregnancy-A randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2019;236:46–52.
   PubMed Web of Science ®Google Scholar
• Dhananjaya BS, Jamuna R. Oral nifedipine versus intravenous labetalol in hypertensive emergencies of pregnancy: a randomised trial. Res J Pharm Biol Chem Sci. 2015;6:1673–1681.
   Google Scholar
• Chen Q, Xiao XR, Zhao MZ, et al. The antihypertensives, nifedipine and labetalol prevent endothelial cell activation in response to placental extracellular vesicles released from 1st trimester placental explants that had been treated with preeclamptic sera. Pregnancy Hypertension: An Int J Women Cardiovascular Health. 2016;6(3):140. DOI:10.1016/j.preghy.2016.08.008
   Google Scholar
• Yang CZ, Zhou Y, Ke M, et al. Effects of postoperative adjuvant steroid therapy on the outcomes of biliary atresia: a systematic review and updated meta-analysis. Front Pharmacol. 2022;13:956093.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions version 6.2. Cochrane; 2021 [updated 2021 Feb; Accessed 2023 Apr 10]. www.training.cochrane.org/handbook
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(oct18 2):d5928. DOI:10.1136/bmj.d5928
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Higgins JPT. Tools for assessing risk of reporting biases in studies and syntheses of studies: a systematic review. BMJ Open. 2018;8(3):e019703.
   PubMed Web of Science ®Google Scholar
• Palma Perez S, Delgado Rodriguez M. Practical considerations on detection of publication bias. Gac Sanit. 2006;20(Suppl 3):10–16.
   PubMedGoogle Scholar
• Dhali B, Bhattacharya S, Ganguly R, et al. A randomized trial of intravenous labetalol and oral nifedipine in severe pregnancy induced hypertension. Int J Reprod Contraception Obstetrics Gynecology. 2012;1:42–46.
   Google Scholar
• Fu ZM, Wang AL, Pei XY. Comparative effects of magnesium sulfate plus nifedipine or labetalol for the treatment of pregnancy-induced hypertension [in Chinese]. Hainan Med J. 2016;27(14):2346–2348.
   Google Scholar
• Gainder S, Thakur M, Saha SC, et al. To study the changes in fetal hemodynamics with intravenous labetalol or nifedipine in acute severe hypertension. Pregnancy Hypertens. 2019;15:12–15.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Khan S, Jain U. A comparative evaluation of intravenous labetalol versus oral nifedipine for control of severe pregnancy-induced hypertension with low-dose regimen. Int JMed Sci Public Health. 2015;5(6):1.
   Google Scholar
• Pei YX, Zhang XY, Li JC, et al. Clinical effect of nifedipine and labetalol in the treatment of severe pregnancy-induced hypertension [in Chinese]. Chinese J Clinical Rational Drug Use. 2015;8(22):91–92.
   Google Scholar
• Raheem IA, Saaid R, Omar SZ, et al. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomised trial. BJOG. 2012;119(1):78–85.
   PubMed Web of Science ®Google Scholar
• Sathya Lakshmi B, Dasari P. Oral nifedipine versus intravenous labetalol in hypertensive urgencies and emergencies of pregnancy: a randomized clinical trial. Obstet Med. 2012;5(4):171–175.
   PubMedGoogle Scholar
• Shekhar S, Sharma C, Thakur S, et al. Oral nifedipine or intravenous labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. Obstet Gynecol. 2013;122(5):1057–1063.
   PubMed Web of Science ®Google Scholar
• Shi DD, Yang FZ, Zhou L, et al. Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. J Clin Pharm Ther. 2016;41(6):657–661.
   PubMed Web of Science ®Google Scholar
• Vermillion ST, Scardo JA, Newman RB, et al. A randomized, double-blind trial of oral nifedipine and intravenous labetalol in hypertensive emergencies of pregnancy. Am J Obstet Gynecol. 1999;181(4):858–861.
   PubMed Web of Science ®Google Scholar
• Wu HZ, Cheng Y, Yu D, et al. Different dosage regimens of nifedipine, labetalol, and hydralazine for the treatment of severe hypertension during pregnancy: a network meta-analysis of randomized controlled trials. Hypertens Pregnancy. 2022;41(2):126–138.
   PubMed Web of Science ®Google Scholar
• Hussein M, Mooij JM, Roujouleh H. Factor analysis, including antihypertensive medication, of the outcome of pregnancy in pregnancy-associated hypertension. Kidney & Blood Pressure Res. 2001;24(2):124–128.
   PubMed Web of Science ®Google Scholar
• Mabie WC, Gonzalez AR, Sibai BM, et al. A comparative trial of labetalol and hydralazine in the acute management of severe hypertension complicating pregnancy. Obstet Gynecol. 1987;70(3 Pt 1):328–333.
   PubMed Web of Science ®Google Scholar
• Mustafa R, Ahmed S, Gupta A, et al. A comprehensive review of hypertension in pregnancy. J Pregnancy. 2012;2012:105918.
   PubMedGoogle Scholar
• Practice CoO. Committee opinion no. 692: emergent therapy for acute-onset, severe hypertension during pregnancy and the postpartum period. Obstetrics Gynecol. 2017;129(4):e90–5. DOI:10.1097/AOG.0000000000002019.
   PubMed Web of Science ®Google Scholar
• Alavifard S, Chase R, Janoudi G, et al. First-line antihypertensive treatment for severe hypertension in pregnancy: a systematic review and network meta-analysis. Pregnancy Hypertens. 2019;18:179–187.
   PubMed Web of Science ®Google Scholar
• Sridharan K, Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol. 2018;84(9):1906–1916.
   PubMed Web of Science ®Google Scholar
• Awaludin A, Rahayu C, Daud NAA, et al. Antihypertensive medications for severe hypertension in pregnancy: a systematic review and meta-analysis. Healthcare (Basel). 2022;10(2):325.
   PubMedGoogle Scholar
• Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy: the task force for the management of cardiovascular diseases during pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(34):3165–3241. DOI:10.1093/eurheartj/ehy340
   PubMed Web of Science ®Google Scholar
• Holbrook B, Nirgudkar P, Mozurkewich E. 574: efficacy of hydralazine, labetalol, and nifedipine for the acute reduction of severe hypertension in pregnancy: a systematic review. Am J Obstet Gynecol. 2015;212(1, Supplement):S286–7.
   Web of Science ®Google Scholar
• Webster LM, Myers JE, Nelson-Piercy C, et al. Labetalol versus nifedipine as antihypertensive treatment for chronic hypertension in pregnancy: a randomized controlled trial. Hypertension (Dallas, Tex: 1979). 2017;70(5):915–922. DOI:10.1161/HYPERTENSIONAHA.117.09972
   PubMed Web of Science ®Google Scholar
• Alavifard S, Chase R, Chaumont A, et al. First-line antihypertensive treatment for severe hypertension in pregnancy: a systematic review and network meta-analysis. Pregnancy Hypertens. 2019;18:179–187.
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. 2011.
   Google Scholar